Page last updated: 2024-08-24

aripiprazole and er-086526

aripiprazole has been researched along with er-086526 in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Kim, HS; Kim, JY; Lee, BM; Tae, IH; Yoon, S1
Jiang, C; Kim, HS; Kim, JR; Lee, JS; Lee, SH; Park, JH; Park, JW; Yoon, S1

Other Studies

2 other study(ies) available for aripiprazole and er-086526

ArticleYear
Low Doses of the Anti-psychotic Drug Aripiprazole Have Strong P-gp-inhibitory Activity and Sensitize Anti-mitotic Drug-resistant Cancer Cells.
    Anticancer research, 2018, Volume: 38, Issue:9

    Topics: Antimitotic Agents; Aripiprazole; ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Cell Survival; DNA Damage; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Furans; Gene Expression Regulation, Neoplastic; Humans; Ketones; Neoplasms; Vincristine

2018
A Low Dose of Aripiprazole Has the Strongest Sensitization Effect Among 19 Repositioned Bipolar Drugs in P-gp-overexpressing Drug-resistant Cancer Cells.
    Anticancer research, 2021, Volume: 41, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antipsychotic Agents; Apoptosis; Aripiprazole; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Repositioning; Drug Resistance, Neoplasm; Furans; G2 Phase Cell Cycle Checkpoints; Humans; Ketones; Mouth Neoplasms; Squamous Cell Carcinoma of Head and Neck; Vincristine

2021